Results 11 to 20 of about 40,229 (203)

Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study

open access: yesAnnals of Clinical Microbiology and Antimicrobials, 2017
Background We assessed the influence of current cefepime minimal inhibitory concentration (MIC) breakpoints and the maximal cefepime dose on treatment outcomes in patients with bacteremia caused by cefepime-susceptible Pseudomonas aeruginosa.
Ting-Yi Su   +5 more
doaj   +2 more sources

Cefepime-Induced Neutropenia: A Case Report and Literature Review

open access: yesClinical Pharmacology: Advances and Applications, 2023
Somaya Koraysh,1 Junais Koleri,2 Maisa Ali2 1Department of Pharmacy, Hamad Bin Khalifa Medical City, Hamad Medical Corporation, Doha, Qatar; 2Department of Infectious Disease, Communicable Disease Center, Hamad Medical Corporation, Doha ...
Koraysh S, Koleri J, Ali M
doaj   +1 more source

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae

open access: yesMicrobiology Spectrum
Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar
S. Albac   +6 more
doaj   +2 more sources

Negative myoclonus as a manifestation of cefepime neurotoxicity

open access: yesClinical Case Reports
Key Clinical Message Negative myoclonus may present in the early stages of cefepime neurotoxicity. Cefepime neurotoxicity typically presents as reduced consciousness, myoclonus, and seizures; however, negative myoclonus is uncommon.
Daichi Umemoto   +2 more
doaj   +2 more sources

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India [PDF]

open access: yes, 2023
In recent times, discovery efforts for novel antibiotics have mostly targeted carbapenemase-producing Gram-negative organisms. Two different combination approaches are pertinent: b-lactam-b-lactamase inhibitor (BL/BLI) or b-lactam-b-lactam enhancer (BL ...
Yesudhason, Bineshlal   +46 more
core   +1 more source

Cefepime

open access: yesMedical Clinics of North America, 1995
Because of the popularity of some third-generation cephalosporins, emergence of resistant organisms (e.g., selected Enterobacteriaceae) that produce inducible and extended-spectrum beta-lactamases has been a problem. Cefepime's twice-a-day dosage schedule and enhanced activity against Enterobacteriaceae and gram-positive organisms give it several ...
B A, Cunha, M V, Gill
openaire   +2 more sources

Monitoring of cefepime in urine by micellar electrokinetic capillary chromatography with ultraviolet detection and liquid chromatography coupled to mass spectrometry. [PDF]

open access: yes, 2018
Cefepime monitoring in urine by micellar electrokinetic capillary chromatography with UV detection and liquid chromatography coupled to mass spectrometry via electrospray ionization is described.
Kummer, Mirjam   +20 more
core   +1 more source

Preparation and Characterization of New Liposomes. Bactericidal Activity of Cefepime Encapsulated into Cationic Liposomes

open access: yesPharmaceutics, 2019
Cefepime is an antibiotic with a broad spectrum of antimicrobial activity. However, this antibiotic has several side effects and a high degradation rate.
Maria Luisa Moyá   +10 more
doaj   +1 more source

Beta-Lactam Probability of Target Attainment Success: Cefepime as a Case Study

open access: yesAntibiotics, 2023
Introduction: Probability of target attainment (PTA) analysis using Monte Carlo simulations has become a mainstay of dose optimization. We highlight the technical and clinical factors that may affect PTA for beta-lactams.
Daniel J. Selig   +3 more
doaj   +1 more source

Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae

open access: yesAntibiotics, 2015
Treatment options for extended-spectrum β-lactamase-producing Enterobacteriaceae are limited. Piperacillin-tazobactam and cefepime represent potential alternative treatment options; however, large prospective studies are lacking.
Allison M. Gibble   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy